Late last year, Novartis (NVS) began marketing a breakthrough gene therapy for treating youngsters with advanced leukemia and slapped a $475,000 price tag on the one-time treatment. The eye-popping number sparked debate, but the drug was quickly deemed cost effective by a nonprofit watchdog.

The controversy is far from over, though.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • It is perhaps a fine irony that the Baird analyst who is quoted above … “Sorry to be Debbie Downer, but Kymriah is never going to provide a positive ROI [return on investment], even at $475,000,” …. has the initials “BS.”
    He may have access to the numbers that are “proprietary” – and know the potential number of patients – but at the price, 2100 treatments (‘not including rebates’ etc) will cost just about $1 Billion USD.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy